🧠 At a glance:
- FY25 PAT: ₹1,911 crore (+15% YoY)
- Revenue: ₹11,516 crore (+7%)
- Q4 PAT: ₹498 crore (+11%)
- Dividend: ₹6/share final, ₹26/share interim = ₹32/share total
👨⚕️ About the Company
Torrent Pharma is the Amitabh Bachchan of Indian pharma – veteran, versatile, and always in the race. It operates in key therapies like cardiology, diabetology, gastro, CNS, and women’s health with presence in India, US, Germany, Brazil, and other markets.
🧑💼 Key Managerial Personnel (KMP)
- Chairman: Samir Mehta
- MD (Incoming): Aman Mehta (taking charge from 1 August 2025)
💰 Financials
| Metric | FY25 | FY24 | YoY Change |
|---|---|---|---|
| Revenue | ₹11,516 cr | ₹10,758 cr | +7% |
| PAT | ₹1,911 cr | ₹1,658 cr | +15% |
| EBITDA | ₹3,837 cr | ₹3,426 cr | +12% |
| Gross Margin | 74.8% | 74.3% | Flat |
🧮 Fair Value (FV) Calculation
- Assuming 15% PAT growth next 2 years → FY27E PAT = ₹2,529 cr
- Target P/E = 30x (large-cap branded pharma avg)
- FV = ₹2,529 × 30 = ₹75,870 cr Market Cap
- Current Shares = ~84 cr → FV per share = ₹903
- CMP: ₹2,280 → Already pricing in optimism
📈 Growth Outlook
- Chronic therapies growth remains strong
- India business beat IPM growth (12% vs 9%)
- Strong US traction; Brazil and currency drag a watchpoint
🧨 EduInvesting Take
- It’s a classic compounding story, but not undervalued
- ₹32 dividend = 1.4% yield – sweet but not juicy
- FY25 was solid. Unless earnings accelerate, it’s likely to range
- Rating: “Multivitamin stock” – Safe, useful, not thrilling
